Hematological toxicities of immune checkpoint inhibitors and the impact of blood transfusion and its microbiome on therapeutic efficacy and recipient's safety and survival outcome:A systematic narrative appraisal of where we are now!

[1]  J. Amiral,et al.  Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes , 2022, Transfusion and Apheresis Science.

[2]  Jerard Seghatchian.  Spotlight on SARS CoV-2 infection inducing autoimmunity, through the formation of autoantibody to self hemostatic components or to host cells, often leading to severe thrombotic or bleeding events , 2022, Transfusion and Apheresis Science.

[3]  A. Heine,et al.  Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors , 2022, Frontiers in Immunology.

[4]  Xinwei Wu,et al.  Variations in oral microbiome and its predictive functions between tumorous and healthy individuals. , 2022, Journal of medical microbiology.

[5]  A. Geraldo,et al.  The effect of probiotic use on ABO antibody titers , 2022, Immunohematology.

[6]  A. Naing,et al.  Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience , 2022, Journal of hematology.

[7]  A. Wolanskyj-Spinner,et al.  Immunotherapy-associated Autoimmune Hemolytic Anemia. , 2022, Hematology/oncology clinics of North America.

[8]  P. Gilbar,et al.  Case reports of acquired thrombotic thrombocytopenic purpura attributed to pembrolizumab. , 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[9]  Huiqin Jiang,et al.  The Association between Pretreatment anemia and Overall Survival in Advanced Non-small Cell lung Cancer: A Retrospective Cohort Study Using Propensity Score Matching , 2022, Journal of Cancer.

[10]  J. Brahmer,et al.  Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review , 2021, Annals of Hematology.

[11]  C. Berking,et al.  Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis , 2021, Frontiers in Oncology.

[12]  G. Otterson,et al.  Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival , 2021, Cancer Immunology, Immunotherapy.

[13]  F. Petrelli,et al.  Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review , 2021, Frontiers in Immunology.

[14]  Y. Jeon,et al.  Blood transfusion had no influence on the 5-year biochemical recurrence after robot-assisted radical prostatectomy: a retrospective study , 2021, BMC Urology.

[15]  C. Solinas,et al.  Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2021, Targeted Oncology.

[16]  Y. Lou,et al.  Immune‐related hematologic adverse events in the context of immune checkpoint inhibitor therapy , 2021, American journal of hematology.

[17]  V. Wong,et al.  Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors , 2021, Journal of the advanced practitioner in oncology.

[18]  C. Berking,et al.  Hematological immune related adverse events after treatment with immune checkpoint inhibitors. , 2021, European journal of cancer.

[19]  M. Thomas,et al.  How I treat microangiopathic hemolytic anemia in patients with cancer , 2021, Blood.

[20]  A. Zaniboni,et al.  Red blood cell transfusions and the survival in patients with cancer undergoing curative surgery: a systematic review and meta-analysis , 2021, Surgery Today.

[21]  K. Devarajan,et al.  180 The effect of packed red blood cell transfusions on the clinical efficacy of immunotherapy , 2020 .

[22]  S. Stowell,et al.  Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy , 2020, Transfusion.

[23]  B. Lash,et al.  Thrombotic Thrombocytopenic Purpura Induced by Immune Checkpoint Inhibitiors: A Case Report and Review of the Literature , 2020, Cureus.

[24]  T. Carson,et al.  Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review , 2020, Gut Pathogens.

[25]  B. Weiner,et al.  Intervention strategies for microbial therapeutics in cancer immunotherapy , 2020, Immuno-oncology technology.

[26]  M. Matsumoto,et al.  Pembrolizumab-induced Pure Red Cell Aplasia Successfully Treated with Intravenous Immunoglobulin , 2020, Internal medicine.

[27]  E. Haralambieva,et al.  Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect , 2020, BMC Cancer.

[28]  S. Zschiedrich,et al.  Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma , 2020, CEN Case Reports.

[29]  H. Abdel-Razeq,et al.  Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. , 2019, Critical reviews in oncology/hematology.

[30]  A. Raina,et al.  Pembrolizumab-induced thrombotic thrombocytopenic purpura , 2019, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[31]  O. Lambotte,et al.  Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? , 2019, European journal of cancer.

[32]  M. Davies.  Acute and Long-term Adverse Events Associated With Checkpoint Blockade. , 2019, Seminars in oncology nursing.

[33]  R. Dronca,et al.  Immune Checkpoint Inhibitor Toxicities. , 2019, Mayo Clinic proceedings.

[34]  S. Minatoguchi,et al.  Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer , 2019, Respiratory medicine case reports.

[35]  I. Siddiqi,et al.  Bone Marrow Findings of Immune-Mediated Pure Red Cell Aplasia Following Anti-Programmed Cell Death Receptor-1 Therapy: A Report of Two Cases and Review of Literature , 2019, Journal of hematology.

[36]  D. Leaf,et al.  Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors , 2019, American journal of hematology.

[37]  N. M. La‐Beck,et al.  Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines , 2019, Asia-Pacific journal of oncology nursing.

[38]  B. Helmink,et al.  The microbiome, cancer, and cancer therapy , 2019, Nature Medicine.

[39]  K.,et al.  Hematologic Complications of Immune Checkpoint Inhibitors , 2019, The oncologist.

[40]  R. Munker,et al.  Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review , 2018, European journal of haematology.

[41]  C. Robert,et al.  Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. , 2019, The Lancet. Haematology.

[42]  T. Dragovich,et al.  Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors , 2018, Case reports in hematology.

[43]  R. Demontis,et al.  Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach , 2018, Front. Physiol..

[44]  S. Konoplev,et al.  Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab. , 2018, Blood advances.

[45]  Y. Wan,et al.  Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies , 2018, Drug design, development and therapy.

[46]  M. Suarez‐Almazor,et al.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  M. Satoh,et al.  Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. , 2018, Immunotherapy.

[48]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[49]  Q. Hill,et al.  Autoimmune hemolytic anemia. , 2015, Hematology. American Society of Hematology. Education Program.

[50]  A. Gallamini,et al.  Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report , 2017, Hematological oncology.

[51]  T. Takenouchi,et al.  A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma , 2017, Melanoma research.

[52]  D. Yuce,et al.  Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient , 2017, Oncology Research and Treatment.

[53]  J. Seghatchian,et al.  Transfusion-related immunomodulation and cancer. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[54]  J. Seghatchian,et al.  Red blood cell transfusion and outcome in cancer. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[55]  G. Ragab,et al.  The microbiome and transfusion in cancer patients. , 2017, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[56]  P. Coppo,et al.  Thrombotic thrombocytopenic purpura. , 2017, Blood.

[57]  J. Lutzky,et al.  Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP) , 2017, Journal of Immunotherapy for Cancer.

[58]  J. McQuade,et al.  Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy , 2017, Journal of Immunotherapy for Cancer.

[59]  U. Khan,et al.  Immunotherapy-associated autoimmune hemolytic anemia , 2017, Journal of Immunotherapy for Cancer.

[60]  R. Means.  Pure red cell aplasia. , 2016, Hematology. American Society of Hematology. Education Program.

[61]  Devin Kennedy,et al.  Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy , 2016, Case Reports in Oncology.

[62]  G. Kristiansen,et al.  Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia , 2016, Case Reports in Oncology.

[63]  F. Servant,et al.  Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing , 2016, Transfusion.

[64]  R. Kefford,et al.  Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. , 2016, Melanoma research.

[65]  S. Nair,et al.  Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. , 2016, The New England journal of medicine.

[66]  J. Seghatchian,et al.  Impact of Transfusion on Cancer Growth and Outcome , 2016, Cancer growth and metastasis.

[67]  K. Kabashima,et al.  Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cells. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  D. Agrawal,et al.  Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. , 2015, Translational research : the journal of laboratory and clinical medicine.

[70]  R. Das,et al.  Anemia in malignancies: Pathogenetic and diagnostic considerations , 2015, Hematology.

[71]  P. Ascierto,et al.  Serious haematological toxicity during and after ipilimumab treatment: a case series , 2014, Journal of Medical Case Reports.

[72]  G. Niklas Norén,et al.  vigiGrade: A Tool to Identify Well-Documented Individual Case Reports and Highlight Systematic Data Quality Issues , 2013, Drug Safety.

[73]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[74]  T. Gajewski,et al.  Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma , 2009, Cancer Immunology, Immunotherapy.

[75]  David Mackey,et al.  MAMPs and MIMPs: proposed classifications for inducers of innate immunity , 2006, Molecular microbiology.

[76]  M. Pescatori,et al.  Perioperative blood transfusions for the recurrence of colorectal cancer. , 2004, The Cochrane database of systematic reviews.

[77]  S. Wade,et al.  Prevalence and outcomes of anemia in cancer: a systematic review of the literature. , 2004, The American journal of medicine.

[78]  H. Ludwig,et al.  Symptomatology of anemia. , 2001, Seminars in oncology.

[79]  G. Demetri.  Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy , 2001, British Journal of Cancer.

[80]  F. Schildberg,et al.  Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  M. R. Mickey,et al.  Effect of blood transfusions on subsequent kidney transplants. , 1973, Transplantation proceedings.